Fosphenytoin Sodium and Kymriah

• Generic Name: fosphenytoin
• Dosage Forms: n.a.
• Other Brand Names: Cerebyx

Treatment of generalized tonic-clonic status epilepticus.

Benzodiazepines (e.g., diazepam, lorazepam, midazolam) are considered drugs of choice for initial treatment of status epilepticus; IV fosphenytoin (or phenytoin) may be used as a second-line agent if seizures continue.

IV fosphenytoin appears to be better tolerated than IV phenytoin (e.g., fewer adverse cardiovascular effects), and some experts state that fosphenytoin is preferred when both agents are available.

Compared with IV phenytoin, IV fosphenytoin sodium is associated with fewer infusion site reactions (e.g., erythema, pain, burning, swelling, pruritus, soft tissue damage, phlebitis, necrosis) and less frequent need for infusion rate reduction, infusion interruption, and/or changes of infusion sites, but is associated with a higher incidence of systemic sensory disturbances (e.g., burning, paresthesia, pruritus).

Prevention and treatment of seizures occurring during neurosurgery.

May be used as a short-term parenteral replacement for oral phenytoin; because of risks associated with parenteral administration, manufacturer states fosphenytoin should only be used when oral phenytoin not possible.

• Generic Name: tisagenlecleucel
• Dosage Forms: n.a.
• Other Brand Names: Kymriah

Kymriah (tisagenlecleucel) is an immunotherapy medicine used to treat a certain type of acute lymphoblastic leukemia in people who are up to 25 years old.

Kymriah is also used to treat certain adult patients with large B-cell lymphoma.

Kymriah is given after other treatments have failed.

Kymriah is made from your own white blood cells, removed from a small amount of blood drawn from your body.

Kymriah is available under a special program. You must be registered in the program and understand the risks and benefits of this medicine.